Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | CTSA | P10619 | 6/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGAV | P06756 | 2/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | EEF2K | O00418 | 1/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.43 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630103 | 1.00 | PRNP (0.51) | PRNPNPSR1RXFP1CTSAFFAR1 | |
| SCHEMBL6859119 | 0.85 | SMN1; SMN2 (0.53) | PRNPNPSR1RXFP1CTSAFFAR1 | |
| SCHEMBL3781378 | 0.85 | KMT2A (0.47) | KMT2ACYP26A1 | |
| SCHEMBL15654637 | 0.85 | CYP26A1 (0.58) | CTSAPOLBCYP26A1 | |
| SCHEMBL2851129 | 0.84 | KMT2A (0.58) | KMT2AMAPK1CYP26A1 | |
| SCHEMBL3375103 | 0.84 | KMT2A (0.58) | KMT2AMAPK1CYP26A1 | |
| SCHEMBL640977 | 0.84 | KMT2A (0.58) | KMT2AMAPK1CYP26A1 | |
| SCHEMBL15655244 | 0.83 | CYP26A1 (0.58) | CTSAFFAR1KMT2ACYP26A1 | |
| SCHEMBL4011433 | 0.81 | CYP26A1 (0.58) | CTSAITGB3ITGAVITGA2BKMT2A | |
| SCHEMBL6351508 | 0.81 | PRNP (0.52) | PRNPNPSR1RXFP1CTSAITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252393-B1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | EVONIK DEGUSSA GMBH (DE) | 2014-04-30 | — | — | EP | disclosed |
| EP-1694630-B1 | METHOD FOR PRODUCING CHIRAL OR ENANTIOMER-ENRICHED BETA-AMINO ACIDS, -ALDEHYDES, -KETONES AND GAMMA-AMINO ALCOHOLS | DSM FINE CHEM AUSTRIA GMBH (AT) | 2008-05-07 | — | — | EP | disclosed |
| US-20070123589-A1 | Method for producing chiral or enantiomer-enriched beta-amino acids, aldehydes, ketones and gama-amino alcohols | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-05-31 | — | — | US | disclosed |
| EP-1694630-A1 | IMPROVED METHOD FOR PRODUCING CHIRAL OR ENANTIOMER-ENRICHED BETA-AMINO ACIDS, -ALDEHYDES, -KETONES AND GAMMA-AMINO ALCOHOLS | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005063682-A1 | IMPROVED METHOD FOR PRODUCING CHIRAL OR ENANTIOMER-ENRICHED BETA-AMINO ACIDS, -ALDEHYDES, -KETONES AND GAMMA-AMINO ALCOHOLS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123589-A1 | Method for producing chiral or enantiomer-enriched beta-amino acids, aldehydes, ketones and gama-amino alcohols | GLRA1, GLRB, GLRA2 | PRNP 3963/4885NPSR1 1462/4885RXFP1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.